BioCentury
ARTICLE | Company News

Boehringer to acquire Funxional's somatotaxin portfolio

July 24, 2012 1:27 AM UTC

Funxional Therapeutics Ltd. (Cambridge, U.K) and Boehringer Ingelheim GmbH (Ingelheim, Germany) said Boehringer will acquire exclusive, worldwide rights to Funxional's somatotaxin portfolio. The portfolio's most advanced product is FX125L, an oral somatotaxin that has completed a Phase II trial for inflammatory conditions. Details were not disclosed.

The deal also includes backup somatotaxins, including oral FX141L and topical FX87L. Boehringer plans to initially develop FX125L for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Somatotaxins are a class of anti-inflammatory small molecules targeting somatostatin receptor 2 (SSTR2). ...